Predicting Preterm Birth

Two organizations team up in an effort to predict risk of premature birth using big data and genomics.

Written byTracy Vence
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

WIKIMEDIA, ANDRE ENGELSThough it affects one out of every nine babies born in the United States, scientists know surprisingly little about what causes preterm birth. To address the issue, two organizations are hedging their bets on big data and genomics, partnering to develop computer models that can predict the risk that a woman’s child will be born before reaching 37 weeks of gestation.

The Cambridge, Massachusetts-based big data firm GNS Healthcare is collaborating with the Inova Translational Medicine Institute (ITMI) at Inova Fairfax Hospital to mine next-generation sequencing data and electronic medical records gathered by Inova using GNS’s analytics platform, with the goal of commercializing preterm birth predictive models and corresponding software.

“The causes of preterm birth are complex and in about half of cases, are unknown,” the GNS and Inova noted in their announcement. “While there is understood to be a genetic component, no individual genes have been identified as causative to date.”

Researchers at the ITMI are currently following a cohort of 285 premature babies as part of a larger preterm birth study involving 826 families. “Partnering with our colleagues at GNS provides the best opportunity ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies